Blood-brain barrier permeability and bioavailability of a highly potent and/μ-selective opioid receptor antagonist, CTAP: Comparison with morphine

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 402-409

  Abbruscato, Thomas J ^a   Thomas, Sarah A ^a   Hruby, Victor J ^b   Davis, Thomas P ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINETHREONYLAMIDE; INULIN; MORPHINE; MU OPIATE RECEPTOR; OCTAPEPTIDE; OPIATE ANTAGONIST; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG PROTEIN BINDING; ISOTOPE LABELING; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; INULIN; MICE; MORPHINE; NARCOTIC ANTAGONISTS; NARCOTICS; PEPTIDES; PERMEABILITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SOLUBILITY;

EID: 0030893316     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ABBRUBCATO, T. J., WILLIAMS, S. A., HRUBY, V. J. AND DAVIS, T. P.: Blood-to-CNS entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. J. Pharmacol. Exp. Ther. 276: 1049-1057, 1996.
2. BANKS, W. A. AND KASTIN, A. J.: Bi-directional passage of peptides across the blood-brain barrier. Prog. Brain Res. 91: 139-148, 1992.
3. BANKS, W. A. AND KASTIN, A. J.: Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: Comparison with morphine. Peptides 15: 23-29, 1994.
4. BANKS, W. A., SCHALLY, A. V., BARRERA, C. M., FASOLD, M. B., DURHAM, D. A., CSERNUS, V. J., GROOT, K. AND KASTIN, A. J.: Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. U.S.A. 87: 6762-6766, 1990.
5. BRADBURY, M. W. B.: The Concept of the Blood-Brain Barrier, John Wiley and Sons. New York, 1979.
6. BROWNSON, E. A., ABBRUSCATO, T. J., GILLESPIE, T. J., HRUBY, V. J. AND DAVIS, T. P.: Effect of peptidases at the blood-brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. 270: 675-680, 1994.
7. CAI, R.-Z., KARASHIMA, T., GUOTH, J., SZOKE, B., OLSEN, D. AND SCHALLY, A. V.: Superactive octapeptide somatostatin analogs containing tryptophan at position 1. Proc. Natl. Acad. Sci. U.S.A. 84: 2502-2506, 1987.
8. CAI, R.-Z., SZOKE, B., LU, R., FU, D., REDDING, T. W. AND SCHALLY, A. V.: Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. U.S.A. 83: 1896-1900, 1986.
9. CRAIN, S. M. AND SHEN, K.-F.: After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition. J. Pharmacol. Exp. Ther. 260: 182-186, 1992.
10. DAVIS, T. P. AND CULLING-BERGLUND, A.: High-performance liquid Chromatographic analysis of in vitro central neuropeptide processing. J. Chromatogr. 327:279-292, 1985.
11. DAVSON, H., KLEEMAN, C. R. AND LEVIN, E.: Blood-brain barrier and extracellular space. J. Physiol. (Lond.) 159: 1961.
12. ERCHEGYI, J., KASTIN, A. J., ZADINA, J. E. AND Qui, X.-D.: Isolation of a heptapeptide Val-Val-Tyr-Pro-Trp-Thr-Gln (valorphin) with some opiate activity. Int. J. Peptide Protein Res. 39: 477-488, 1991.
13. GOODMAN, L. S. AND GILMAN, A. G.: The Pharmacological Basis of Therapeutics, 9th ed., 550-551, 1996.
14. 61-64 possessing selective agonist activity at mu-opiate receptors. Eur. J. Pharmacol. 70: 531-540, 1981.
15. KARASHIMA, T. AND SCHALLY, A. V.: Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats. Peptides 9: 561-565, 1988.
16. KAZMIERSKI, W., WIRE, W. S., LUI, G. K. KNAPP, R. J., SHOOK, J. E., BURKS, T. P., YAMAMURA, H. I. AND HRUBY, V. J.: Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. J. Med. Chem. 31: 2170-2177, 1988.
17. KRAMER, T. H., SHOOK, J. E., KAZMIERSKI, W., AYRES, E. A., WIRE, W. S., HRUBY, V. J. AND BURKS, T. F.: Novel peptidic mu opioid antagonists: Pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 249: 544-549, 1989.
18. LAMBERTS, S. W. J.: Non-pituitary action of somatustatin: A review on the therapeutic role of SMS 201-995 (Sandostatin). Acta Endocrinol. 112: suppl. 276, 41-55,1986.
19. LAMBERTS, S. W. J.: A guide to the clinical use of the sornatostatin analog SMS201-995H (Sandostatin. Acta Endocrinol. 116: suppl. 286, 54-66, 1987.
20. LASZLO, F., PAVO, I., PENKE, B. AND BALINT, G. A.: Protective effect of an orally administered, highly potent somatostatin analog (RC-1211 against absolute ethanol-induced hemorrhagic erosions of rat gastric mucosa, Life Sci. 44: 1573-1578, 1989.
21. LORD, J. A. H., WATERFIELD, A. A., HUGHES, J. AND KOSTERLITZ, H. W.: Endogenous opioid peptides: Multiple agonists and receptors. Nature (Lond.) 267: 495-499, 1977.
22. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDAL., R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
23. MALDONADO, R., NEGUS, S. AND KOOB, G. F.: Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology 31: 1231-1241, 1992.
24. MARTIN, W. R., EADES, C. G., THOMPSON, J. A., HUPPLER, R. E. AND GILBERT, P. E.: The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197: 517-532, 1976.
25. MOSBERG, H. I., HURST, R., HRUBY, V. J., GEE, K. YAMAMURA, H. I., GALLIGAN, J. J. AND BURKS, T. F.: Bis-penicillamine enkephalins possess highly improved specificity toward delta-opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 80: 5871-5874, 1983.
26. NESTLER, E. J.: Cellular responses to chronic treatment with drugs of abuse. Crit. Rev. Neurobiol. 7: 23-29, 1993.
27. PARDRIDGE, W. M., EISENBERG, J. AND YAMADA, T.: Rapid sequestration and degradation of somatostatin analogues by isolated brain microvessels. J. Neurochem. 44: 1178-1184, 1985.
28. PASTERNAK, G. W.: Pharmacological mechanisms of opioid analgesics, Clin. Neuropharmacol. 16: 1-18, 1993.
29. PAULUS, H.: A rapid and sensitive method for measuring the binding of radioactive Ligands to proteins. Anal, Biochem. 32: 91-100, 1969.
30. PELTON, J. T., GULYA, K., HRUBY, V. J., DUCKLES, S. P. AND YAMAMURA, H. I.: Conformationally restricted analogs of somatostatin with high mu-opiate receptor specificity. Proc. Natl. Acad. Sci. U.S.A. 82: 236-238, 1985.
31. PELTON, J. T., KAZMIKRSKI, W., GULYA, K., YAMAMURA, H. I. AND HRUBY, V. J.: Design and synthesis of somatostatin analogs with high potency and specificity for mu opioid receptors. J. Med. Chem. 29: 2370-2374, 1986.
32. SCHALLY, A. V., CAI, R.-Z., TORRES-ALEMAN, I., REDDING, T. W., SZOKE, B., FU, D., HIEROWSKI, M. T., COLALUCA, J. AND KONTIREK. S.: In Neural and Endocrine Peptides and Receptors, ed. by T. W. Moody, pp. 73-88, Plenum, New York, 1986.
33. SHOOK, J. E., PELTON, J. T., LEMCKE, P. K., PORRECA, F., HRUBY, V. J. AND BURKS, T. F.: Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: Identification of mu receptor-related functions, J. Pharmacol. Exp. Ther. 242: 1-7, 1987.
34. TAKASATO, Y., RAPOPORT, S. I. AND SMITH, Q. R.: An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247: H484-H493, 1984.
35. TERENIUS, L.: Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors. Eur. J. Pharmacol. 38: 211-215, 1976.
36. TRIGUEERO, D., BUCIAK, J. B., YANG, J. AND PARDRIDGE, W. M.: Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54: 1882-1888, 1990.
37. VONVOIGTLANDER, P. F., LAHTI, R. A. AND LUDENS, J. H.: U-50,488: A selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224:7-12, 1983.
38. WANG, Z., BILSKY, E. J., PORRECA, F. AND SADEE, W.: Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence, Life Sci. 54: PL339-PL350, 1994.
39. 5]enkephalin opioid analogs, J. Pharmacol. Exp. Ther. 266: 1649-1655, 1993.
40. 5]enkephalin after intraperitioneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 263: 1308-1316, 1991.
41. 5]enkephalin and two halogenated analogs after intravenous administration. J. Pharmacol. Exp. Ther. 259:1109-1117, 1992.
42. WILLIAMS, S. A., ABBRUSCATO, T. J., HRUBY, V. J. AND DAVIS, T. P.: The passage of a delta-opioid receptor selective enkephalin, DPDPE, across the blood-brain and/or the blood-cerebrospinal fluid barriers. J. Neurochem. 66: 1289-1299, 1996.
43. ZLOKOVIC, B. V., BEGLEY, D. J., DJURICIC, B. M. AND MITROVICK, D. M.: Measurement of solute transport across the blood-brain barrier in the perfused guinea-pig brain: Method and application to N-methyl-α-aminoisobutyric acid. J. Neurochem. 46: 1444-1451, 1986.